Form 4 for MRK Merck & Co.
Accepted 2023-11-09 00:00:00 ET · period of report 2023-11-08 · accession 0001127602-23-027077 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-09 | 2023-11-08 | MRK | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | S - Sale | $105.03 | -43.8K | 111.8K | -28% | -$4.60M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-08 | S | D | 43,823 | $105.03 | 111,763.59 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.0000 to $105.0750, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. (F2) Holdings include shares acquired in dividend reinvestment transactions. |